Scleroderma renal crisis as the sole presenting feature of systemic sclerosis in a postpartum woman
暂无分享,去创建一个
R. Ionescu | C. Cobilinschi | C. Cobilinschi | D. Opris-Belinski | A. Constantinescu | D. Opriș-Belinski
[1] Isac Davidson Santiago Fernandes Pimenta,et al. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis , 2021, Advances in Rheumatology.
[2] V. Vilela,et al. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. , 2016, Revista Brasileira de Reumatologia.
[3] D. Furst,et al. Update of EULAR recommendations for the treatment of systemic sclerosis , 2015, Annals of the rheumatic diseases.
[4] S. Lakshminarayanan,et al. Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature. , 2015, Clinical and experimental rheumatology.
[5] S. Bhavsar,et al. Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease. , 2014, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[6] C. Denton,et al. 320. The Prognosis of Scleroderma Renal Crisis in RNA-Polymerase III Antibody-Positive Compared to Rna-Polymerase III Antibody-Negative Patients , 2014 .
[7] D. Huscher,et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group , 2014, Annals of the rheumatic diseases.
[8] L. Punzi,et al. Prognosis of scleroderma renal crisis: a long-term observational study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] J. Bijlsma,et al. Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. , 2013, Clinical and experimental rheumatology.